<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20032">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01941511</url>
  </required_header>
  <id_info>
    <org_study_id>B5201001</org_study_id>
    <secondary_id>B5201001</secondary_id>
    <nct_id>NCT01941511</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of IV Doses of Gmi-1070 on Qtc Intervals in Healthy African-American Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, 3-way, Crossover Single Dose, Placebo, and Active Controlled Study to Evaluate the Effect of Intravenous Doses of Gmi-1070 on Qtc Intervals in Healthy African-American Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of
      GMI-1070 in African-American Adult subjects.  This is conducted as part of standard drug
      development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
  <primary_outcome>
    <measure>QTc, during rivipansel treatment period</measure>
    <time_frame>prior to dose, through 72 hours after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QTc, using Fridericia's correction method (QTcF) at each time point during rivipansel treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTc, during  placebo treatment period</measure>
    <time_frame>prior to dose, through 72 hours after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QTc, using Fridericia's correction method (QTcF) at each time point during placebo treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTc,  during moxifloxacin treatment period</measure>
    <time_frame>prior to dose, through 72 hours after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QTcF, or any other appropriate correction method at each postdose time point of moxifloxacin treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rivipansel/Placebo/Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivipansel</intervention_name>
    <description>Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.</description>
    <arm_group_label>Rivipansel/Placebo/Moxifloxacin</arm_group_label>
    <other_name>GMI-1070</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy African-American male and/or female subjects of non-childbearing potential
             between the ages of 18 and 55 years, inclusive.

        Exclusion Criteria:

          -  Pregnant females; breastfeeding females; and females of childbearing potential. Males
             who are unwilling or unable to use 2 highly effective method of contraception for the
             duration of the study starting at least 14 days prior to the first dose of
             investigational product and for at least 28 days after the last dose of
             investigational product.

          -  Non African-American.

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated,
             asymptomatic,seasonal allergies at the time of dosing).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5201001&amp;StudyName=A%20Study%20to%20Evaluate%20the%20Effect%20of%20IV%20Doses%20of%20Gmi-1070%20on%20Qtc%20Intervals%20in%20Healthy%20African-American%20Adult%20Subjects%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QTc</keyword>
  <keyword>African-American</keyword>
  <keyword>GMI-1070</keyword>
  <keyword>QT/QTc interval prolongation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
